NV5 Global (NVEE) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Richard Tong - Director, EVP & General CounselDickerson Wright - Executive ChairmanBen Heraud - CEOEdward Codispoti - CFOAlexander Hockman - President & CEO - InfrastructureAndrew Chang - COO - Buildings & TechnologyKurt Allen - President of GeospatialSam Kusswurm - Equity Research Associate Conference Call Participants Chris Moore - Senior AnalystRob Brown - Founding Partner & Senior Research AnalystAndrew Wittmann - Seni ...

Financial Data and Key Metrics Changes - IDACORP's diluted earnings per share increased to $1.1 from $0.95 in the first quarter of the previous year [5] - Net income rose by $11.4 million compared to the first quarter last year, primarily driven by higher retail revenues and incremental tax credits [19] - The company reaffirmed its full-year diluted earnings per share guidance range of $5.65 to $5.85 [5][36] Business Line Data and Key Metrics Changes - Retail customer growth was reported at 2.6%, with residential customer growth at 2.9% [6] - Retail revenues per megawatt hour increased, contributing an additional $11.3 million to operating income [20] - Other operating and maintenance expenses rose by $7.2 million, largely due to wildfire mitigation program costs [21] Market Data and Key Metrics Changes - The five-year forecast for retail sales growth is projected at 8.3% annually, necessitating additional system investments [9] - The company expects good hydropower generation in 2025, ranging from 7 million to 8.5 million megawatt hours [38] Company Strategy and Development Direction - The company is focused on executing infrastructure projects to meet customer demand, with significant investments planned [10][27] - IDACORP is actively monitoring tariffs and regulatory changes to ensure affordability for customers [13] - A general rate case is planned to recover substantial capital investments, with rates expected to be effective no earlier than January 2026 [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in customer growth and economic expansion within Idaho Power's service area [6] - The company is committed to maintaining a strong balance sheet while targeting a 50/50 debt-equity capital ratio [29] - Management highlighted the importance of timely recovery mechanisms for infrastructure investments to reduce regulatory lag [81] Other Important Information - The company is actively engaged in discussions regarding wildfire mitigation plans and legislative changes [16][90] - A significant expansion project by Chobani and a new distribution center by Tractor Supply Company were noted as indicators of strong customer interest [6][8] Q&A Session Summary Question: Changes to wildfire mitigation plans due to new legislation - Management does not anticipate significant changes to the wildfire mitigation program but may make modifications over time [42] Question: Thoughts on rate case mechanisms to improve ROEs - The company is preparing its case and considering options to reduce regulatory lag [44] Question: Impact of chaotic periods on the agricultural community - Management noted it is too early to measure impacts but remains optimistic about agricultural conditions [54] Question: Capacity for proposing multiyear mechanisms to the PUC - Management is open to discussing creative solutions to help with the volume of filings [60] Question: Status of contract negotiations with a data center - Ongoing negotiations are still in progress [78] Question: Timely recovery of transmission project costs - Management is exploring various mechanisms for timely cost recovery [80]

Financial Data and Key Metrics Changes - Ascendis Pharma reported a significant increase in first quarter revenue for Europath, reaching €44.7 million, up from €13.6 million in the previous quarter [28] - Total revenue for the first quarter was €101 million, which includes non-product revenue from collaboration partners [30] - R&D costs for the first quarter totaled €86.6 million, compared to €70.7 million in the same quarter of the previous year [30] - SG&A expenses increased to €101 million from €66.8 million year-over-year, primarily due to global commercial expansion [31] Business Line Data and Key Metrics Changes - Europath's global revenue grew to €45 million in the first quarter, reflecting strong U.S. demand and a growing patient base [13][28] - Skytrofa generated €51.3 million in revenue for the quarter, with stable pricing and market share despite seasonal impacts [29][19] - The company expects Europath to significantly contribute to revenue in 2025, with a potential to become a multi-billion euro product [18] Market Data and Key Metrics Changes - In the U.S., Europath was prescribed by over 1,000 unique prescribers for more than 1,750 patients, marking a successful launch [11] - The company estimates there are over 400,000 patients globally with chronic hypoparathyroidism, with 70,000 in the U.S. alone [18] - Skytrofa holds approximately 7% market share in the total growth hormone market in the U.S. and around 43% in the non-active growth hormone market [19] Company Strategy and Development Direction - Ascendis Pharma aims to be a leading biopharma company, focusing on the commercialization and development of Skytrofa and Europath [10] - The company is committed to expanding its product portfolio, with TransCon CNP being a key component in treating achondroplasia [12] - Ascendis Pharma is exploring market opportunities beyond endocrinology and rare diseases, indicating a strategic shift towards broader therapeutic areas [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong launch of Europath and its potential to become cash flow positive [10] - The company anticipates substantial revenue growth driven by the global launch of Europath and continued contributions from Skytrofa [32] - Management highlighted the importance of addressing unmet medical needs and the positive trends in reimbursement for Europath [38][40] Other Important Information - Ascendis Pharma's proprietary TransCon technology platform is fundamental to the development of its medicines, allowing for differentiated treatment benefits [26] - The company is collaborating with Novo Nordisk for the development of TransCon technology-based products in metabolic and cardiovascular diseases [27] Q&A Session Summary Question: What is the expected reimbursement rate for Yorvapath? - Management estimates that 17% to 18% of patients will ultimately get reimbursed once Yorvapath reaches steady state [38] Question: Can you provide the split between U.S. and ex-U.S. revenue for Yorvapath? - Management indicated that while specific numbers are not disclosed, there is steady growth expected outside the U.S. with an acceleration anticipated in the second half of the year [48] Question: What is the depth of prescribing for Yorvapath? - Management noted that they cannot definitively categorize patients as well-controlled or uncontrolled but expect a steady flow of patients transitioning from conventional therapies [66][70] Question: How is the company addressing payer dynamics? - Management emphasized that they are well-equipped to navigate reimbursement challenges, leveraging experience from previous product launches [75] Question: What are the competitive dynamics with new entrants in the market? - Management expressed confidence that their product addresses significant unmet medical needs and that new entrants may not significantly impact their market position [114]

AXT (AXTI) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Leslie Green - Investor RelationsGary Fischer - CFO, VP & Corporate SecretaryMorris Young - Co-Founder, CEO & ChairmanRoss Cole - Equity Research AssociateTim Bettles - VP Business Development, Strategic Sales and MarketingMatthew Bryson - MD - Equity Research Conference Call Participants Richard Shannon - Senior Research AnalystDave Kang - Senior Analyst Operator Good afternoon, everyone, and welcome to AXT's First Quarter twent ...

GeoVax Labs (GOVX) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants David Dodd - Chairman, President & CEOMark Reynolds - CFOJames Molloy - Managing Director, Equity Research, Biotechnology & Specialty PharmaceuticalsJeffrey Kraws - Co-Founder & CEO Conference Call Participants Robert Leboyer - Senior Biotechnology Analyst Operator Good afternoon, and welcome everyone to the GeoVax First Quarter twenty twenty five Corporate Update Call. My name is Michelle, and I will facilitate today's c ...

Red Rock Resorts (RRR) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Stephen Cootey - Executive VP, CFO & TreasurerScott Kreeger - PresidentLorenzo Fertitta - Vice Chairman of the BoardJohn Decree - Director - Equity ResearchBarry Jonas - Managing DirectorDavid Katz - Managing DirectorSteven Wieczynski - Managing DirectorFrank Fertitta - Chairman & CEO Conference Call Participants Carlo Santarelli - AnalystShaun Kelley - Senior Research Analyst & MD - Gaming, Lodging & Leisure Equities ...

Traeger (COOK) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Nick Bacchus - VP of IR, Treasury & Capital marketsJeremy Andrus - CEODominic Blosil - Chief Financial OfficerSabrina Baxamusa - Equity Research Associate Conference Call Participants Anna Glaessgen - Senior Research AnalystPeter Benedict - Senior Research AnalystBrian McNamara - MD & Senior Analyst - ConsumerNone - Analyst Operator Good afternoon. Thank you for attending the Traeger First Quarter Fiscal twenty twenty five Ea ...

OneSpan (OSPN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Joe Maxa - VP, IRVictor Limongelli - CEOJorge Martell - CFOTrevor Rambo - Software Equity Research Associate Conference Call Participants Catharine Trebnick - Senior Research AnalystAnja Soderstrom - Senior Equity Research AnalystRudy Kessinger - Managing Director - Senior Equity Research Analyst Operator thank you for standing by. Welcome to the Q1 twenty twenty five OneSpan Earnings Conference Call. At this time, all partic ...

Frontier Group Holdings (ULCC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants David Erdman - Senior Director-Investor RelationsBarry Biffle - CEO, President & DirectorJames Dempsey - PresidentRobert Schroeter - Sr VP, Chief Commercial OfficerMark Mitchell - Senior VP & CFOMichael Linenberg - Managing DirectorSavanthi Syth - MD - Airlines & Advance Air MobilityTom Fitzgerald - VP - Equity ResearchJames Baker - Managing Director & Investment SpecialistDuane Pfennigwerth - Senior Managing ...

OneSpan (OSPN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Joe Maxa - VP, IRVictor Limongelli - CEOJorge Martell - CFOTrevor Rambo - Software Equity Research Associate Conference Call Participants Catharine Trebnick - Senior Research AnalystAnja Soderstrom - Senior Equity Research AnalystRudy Kessinger - Managing Director - Senior Equity Research Analyst Operator thank you for standing by. Welcome to the Q1 twenty twenty five OneSpan Earnings Conference Call. At this time, all partic ...